BI-3406

Last updated

BI-3406
BI-3406 structure.png
Clinical data
Drug class SOS1 inhibitor
Identifiers
  • N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7-methoxy-2-methyl-6-[(3S)-oxolan-3-yl]oxyquinazolin-4-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
PDB ligand
Chemical and physical data
Formula C23H25F3N4O3
Molar mass 462.473 g·mol−1
3D model (JSmol)
  • CC1=NC2=CC(=C(C=C2C(=N1)N[C@H](C)C3=CC(=CC(=C3)N)C(F)(F)F)O[C@H]4CCOC4)OC
  • InChI=1S/C23H25F3N4O3/c1-12(14-6-15(23(24,25)26)8-16(27)7-14)28-22-18-9-21(33-17-4-5-32-11-17)20(31-3)10-19(18)29-13(2)30-22/h6-10,12,17H,4-5,11,27H2,1-3H3,(H,28,29,30)/t12-,17+/m1/s1
  • Key:XVFDNRYZXDHTHT-PXAZEXFGSA-N

BI-3406 is a drug that acts as an inhibitor of the guanine nucleotide exchange factor protein SOS1, and prevents it from binding to its target protein KRAS. It has potential applications in the treatment of cancer, and has been widely used in cancer research either in combination with other drugs or as a lead compound for the development of related compounds. [1] [2] [3] [4] [5] [6] [7]

See also

References

  1. ↑ Ramharter J, Kessler D, Ettmayer P, Hofmann MH, Gerstberger T, Gmachl M, et al. (May 2021). "One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS". Journal of Medicinal Chemistry. 64 (10): 6569–6580. doi:10.1021/acs.jmedchem.0c01949. PMID   33719426.
  2. ↑ Kessler D, Gerlach D, Kraut N, McConnell DB (June 2021). "Targeting Son of Sevenless 1: The pacemaker of KRAS". Current Opinion in Chemical Biology. 62: 109–118. doi:10.1016/j.cbpa.2021.02.014. PMID   33848766.
  3. ↑ Ma Y, Schulz B, Trakooljul N, Al Ammar M, Sekora A, Sender S, et al. (September 2022). "Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines". Cancers. 14 (18): 4467. doi: 10.3390/cancers14184467 . PMC   9497071 . PMID   36139627.
  4. ↑ Daley BR, Vieira HM, Rao C, Hughes JM, Beckley ZM, Huisman DH, et al. (November 2023). "SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status". Proceedings of the National Academy of Sciences of the United States of America. 120 (47) e2313137120. Bibcode:2023PNAS..12013137D. doi: 10.1073/pnas.2313137120 . PMC   10666034 . PMID   37972068.
  5. ↑ Hamilton G, Stickler S, Rath B (2023). "Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras". Current Pharmaceutical Design. 29 (22): 1741–1746. doi:10.2174/1381612829666230418114520. PMID   37073657.
  6. ↑ Thatikonda V, Lyu H, Jurado S, Kostyrko K, Bristow CA, Albrecht C, et al. (September 2024). "Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance". Nature Cancer. 5 (9): 1352–1370. doi:10.1038/s43018-024-00800-6. PMC   11424490 . PMID   39103541.
  7. ↑ Baltanás FC, Kramer-Drauberg M, García-Navas R, Patrucco E, Petrini E, Arnhof H, et al. (March 2025). "SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD". Proceedings of the National Academy of Sciences of the United States of America. 122 (11) e2422943122. Bibcode:2025PNAS..12222943B. doi:10.1073/pnas.2422943122. PMC   11929440 . PMID   40073053.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.